nsf.gov - NCSES Business Research and Development and Innovation: 2008–10 - US National Science Foundation (NSF)
text-only page produced automatically by LIFT Text
Transcoder Skip all navigation and go to page contentSkip top navigation and go to directorate navigationSkip top navigation and go to page navigation
National Science Foundation National Center for Science and Engineering Statistics

General Notes

Data Tables

Appendix A. Technical Notes

Appendix B. Survey Instruments

Suggested Citation, Acknowledgments


Raymond M. Wolfe,
Project Officer
(703) 292-7789
Research and Development Statistics Program

Business Research and Development and Innovation: 2008–10


General Notes


The Business Research and Development and Innovation Survey (BRDIS), successor to the Survey of Industrial Research and Development (SIRD), is the primary source of information on research and development performed by businesses within the 50 states and the District of Columbia. The survey is conducted by the Census Bureau in accordance with an interagency agreement with the National Science Foundation's National Center for Science and Engineering Statistics. BRDIS reports and data can be found at http://www.nsf.gov/statistics/industry/.

BRDIS is an annual, nationally representative sample survey of approximately 43,000 companies, including companies in manufacturing and nonmanufacturing industries. The target population for BRDIS consists of all for-profit companies that have five or more employees and that perform R&D in the United States. The Business Register, a Census Bureau compilation that contains information on more than 3 million establishments with paid employees, serves as the frame from which the survey sample is selected. For companies with more than one establishment, data are summed to the company level. Companies are excluded from the frame if they are classified as farms or have fewer than five employees.

Survey results are used to assess trends in the performance and funding of R&D. Government agencies, corporations, and research organizations use these data to investigate productivity, formulate tax policy, and compare individual company performance with industry averages. Individual researchers in industry and academia use these data to investigate a variety of topics and in preparing professional papers, dissertations, and books. Total R&D expenditure statistics are used by the Bureau of Economic Analysis for inclusion in their System of National Accounts and Foreign Direct Investment programs. Furthermore, BRDIS statistics make it possible to more fully evaluate the status of R&D in the United States and to compare the R&D and innovation activities of the United States with those of other nations. The usefulness of the information collected in this survey is enhanced by linking the data to the Census Bureau's Longitudinal Establishment Data file, which contains information on the outputs and inputs of companies' manufacturing plants. Response to this annual survey is mandatory and confidential under Title 13 of the United States Code.

Terms used in business accounting and incorporated throughout the tables are defined in the technical notes.

Business Research and Development and Innovation: 2008–10
Detailed Statistical Tables | NSF 13-332 | September 2013


Tables 124, 139, and 141 contained errors in data reported and have been replaced with corrected versions. Specific corrections are as follows. Table 124:  total number of full-time equivalent scientists and engineers column for several industries. Table 139: number of companies reporting R&D in the energy application area for mining, extraction, and support activities and other nonmanufacturing industries and in the environmental protection area for agricultural implement and other machinery manufacturing industries. Table 141: number of companies reporting R&D in medical clinical trials for other chemicals and other manufacturing industries, number of companies reporting R&D in nanotechnology for semiconductor machinery and other machinery manufacturing industries, and the amount of domestic R&D paid for in medical clinical trials for other chemicals.